MRK - Why Is Cancer-Focused C4 Therapeutics Stock Soaring Today? | Benzinga
C4 Therapeutics Inc (NASDAQ: CCCC) has entered into an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
Under the terms of the agreement, C4 Therapeutics will receive a $10 million upfront payment.
C4 Therapeutics and Merck will collaborate to develop DACs directed to an initial undisclosed oncology target exclusive ...